FDA Granted Breakthrough Status to Sepsis Therapy
The designation aims to speed up the review of a new device for adults experiencing life-threatening hyperinflammation.
Updated on Oct. 7, 2026 in Diabetes
Live Poll
Should regulatory agencies accelerate approval pathways for experimental medical devices to treat life-threatening conditions?
The FDA has awarded Breakthrough Device Designation to the SeaStar Medical SCD therapy for managing hyperinflammation in adults with sepsis. This status is designed to accelerate the development and assessment of medical devices that offer potential improvements for serious conditions.
Why it matters
Sepsis affects 1.7 million U.S. adults annually and is a factor in nearly one-third of in-hospital deaths. Currently, no FDA-approved therapies specifically target the dysregulated inflammatory host responses that drive these severe outcomes.
The SCD therapy has now received seven Breakthrough Device Designations from the FDA. While clinical trial data for related indications like acute kidney injury have shown high survival rates, the effectiveness of this device specifically for sepsis hyperinflammation is still under study.
The players
SeaStar Medical
A medical technology company focused on developing devices that target dysregulated immune responses in patients with life-threatening conditions.
FDA
The federal regulatory agency responsible for evaluating the safety and efficacy of medical devices before they are made available for clinical use.
The details
The SCD therapy is designed to integrate into standard continuous RRT hemofiltration systems used in clinical settings. Once connected, the device selectively targets proinflammatory monocytes circulating in the blood. By shifting these cells into a reparative state, the technology aims to dampen the systemic hyperinflammation that often characterizes severe sepsis cases.
Timeline
2024: The FDA approved the use of QUELIMMUNE.
February 2026: The QUELIMMUNE SAVE Registry data was published.
October 7, 2026: The FDA officially granted the Breakthrough Device Designation.
Health Landscape
This development represents a shift toward immunomodulatory devices in the critical care landscape. It builds upon the methodology established in the NEUTRALIZE-AKI pivotal trial to address the broader, unmet need of sepsis-related inflammatory surges.
For patients and families navigating critical care, this designation means a potential new treatment pathway is moving through the development pipeline. Any questions regarding current treatment options for sepsis or systemic inflammation should be discussed directly with a physician.
The takeaway
The FDA's designation reflects a focused effort to address the high mortality rates associated with dysregulated inflammation in sepsis. Patients and caregivers should continue to monitor updates from their care team regarding new clinical evidence as it becomes available.
What happens next
SeaStar Medical is preparing to present additional data regarding the sepsis indication to the FDA in the near term.
Further reading
Learn more about the latest innovations in Diabetes care and device technology.
More information
For more details on the therapeutic approach, view the complete risk information for QUELIMMUNE.
Live Poll
Should regulatory agencies accelerate approval pathways for experimental medical devices to treat life-threatening conditions?
